10-KPeriod: FY2005

ABBOTT LABORATORIES Annual Report, Year Ended Dec 31, 2005

Filed February 22, 2006For Securities:ABT

Summary

Abbott Laboratories' 2005 10-K report highlights a year of significant growth and strategic moves within the healthcare sector. The company demonstrated robust performance across its key segments, including Pharmaceutical Products, Diagnostic Products, and Ross Products, with international operations also showing strong contributions. A notable event was the planned acquisition of Guidant's vascular intervention and endovascular solutions businesses, signaling an intent to expand its medical device portfolio. The company continued its focus on innovation, with substantial investments in research and development, particularly in immunology, oncology, and neuroscience. Despite facing patent expirations and increased generic competition for some established products, Abbott managed its portfolio effectively, leveraging new product launches and market expansion to drive overall revenue growth. The spin-off of Hospira in the prior year was successfully completed, allowing Abbott to concentrate on its core health care offerings. The company's financial health remained strong, supported by solid operating cash flows and prudent debt management, positioning it well for future growth and potential strategic acquisitions.

Key Highlights

  • 1Abbott Laboratories operates across four key revenue segments: Pharmaceutical Products, Diagnostic Products, Ross Products, and International.
  • 2The company announced an agreement to acquire Guidant's vascular intervention and endovascular solutions businesses for $4.1 billion, subject to regulatory approvals.
  • 3HUMIRA® sales were strong, reaching $1.4 billion in 2005, a significant increase from $852 million in 2004, contributing to the Pharmaceutical Products segment's growth.
  • 4The company invested heavily in research and development, totaling $1.82 billion in 2005, with a focus on immunology, oncology, neuroscience, diabetes/metabolism, and viral diseases.
  • 5Abbott successfully completed the spin-off of its hospital products business, Hospira, Inc., in April 2004, presenting Hospira's results as discontinued operations.
  • 6Despite generic competition for products like Synthroid® and clarithromycin, Abbott reported an overall net sales increase of 13.5% in 2005.
  • 7The company maintained a strong financial position with $5.0 billion in net cash from operating activities in 2005 and significant credit facilities available.

Frequently Asked Questions

Abbott's growth in 2005 was primarily driven by strong sales in its Pharmaceutical Products segment, notably from HUMIRA®, and continued expansion in its Diagnostic Products and International segments. The acquisition of TheraSense and EAS in 2004 also contributed to revenue growth in the Diagnostic Products and Ross Products segments, respectively.

In 2005, Abbott announced its agreement to acquire Guidant's vascular intervention and endovascular solutions businesses for $4.1 billion. This acquisition, subject to regulatory approval, aimed to strengthen Abbott's position in the cardiovascular market. The company had also successfully completed the spin-off of its hospital products business, Hospira, Inc., in April 2004.

Abbott faced patent expirations and increased generic competition for certain products, such as Synthroid® and clarithromycin. While these factors impacted sales of specific products, Abbott managed this through new product launches, further development of existing products, and effective portfolio management, resulting in overall net sales growth for the company.

Abbott demonstrated a strong commitment to innovation by investing $1.82 billion in research and development in 2005. These investments were primarily focused on developing new pharmaceutical products in key therapeutic areas like immunology, oncology, neuroscience, diabetes/metabolism, and viral diseases.